Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wan-Long Chuang

Showing results (121-130 of 456) with videos related to

Pageof 46
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2011
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic populationChih-Wen Wang, Hsing-Yi Lin, Shyi-Jang Shin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 9, 2021
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide<sup>☆</sup>Ming-Lun Yeh, Po-Cheng Liang, Sam Trinh, et al.
Antiviral Research|July 2, 2003
Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alphaMing-Lung Yu, Chia-Yen Dai, Chao-Chin Chiu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2006
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in TaiwanMing-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, et al.
The Kaohsiung Journal of Medical Sciences|June 12, 2017
Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infectionTa-Ya Lin, Ming-Lun Yeh, Ching-I Huang, et al.
World Journal of Gastroenterology|July 15, 2005
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirinChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Antiviral Research|July 30, 2005
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirinChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 6, 2025
A Point-of-Care Model for Hepatitis C Elimination in Remote Islands of TaiwanTzu-Chun Lin, Pei-Chien Tsai, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|December 12, 2013
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infectionChing-I Huang, Chung-Feng Huang, Jee-Fu Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 6, 2022
Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular CarcinomaYu-Han Huang, Chi Chan, Hye-Won Lee, et al.
Pageof 46

Showing results (121-130 of 456) with videos related to

Sort By:
Pageof 46
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2011
The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic populationChih-Wen Wang, Hsing-Yi Lin, Shyi-Jang Shin, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 9, 2021
Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide<sup>☆</sup>Ming-Lun Yeh, Po-Cheng Liang, Sam Trinh, et al.
Antiviral Research|July 2, 2003
Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alphaMing-Lung Yu, Chia-Yen Dai, Chao-Chin Chiu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 20, 2006
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in TaiwanMing-Lung Yu, Chia-Yen Dai, Zu-Yau Lin, et al.
The Kaohsiung Journal of Medical Sciences|June 12, 2017
Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infectionTa-Ya Lin, Ming-Lun Yeh, Ching-I Huang, et al.
World Journal of Gastroenterology|July 15, 2005
Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirinChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
Antiviral Research|July 30, 2005
Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirinChia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al.
The Kaohsiung Journal of Medical Sciences|June 6, 2025
A Point-of-Care Model for Hepatitis C Elimination in Remote Islands of TaiwanTzu-Chun Lin, Pei-Chien Tsai, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|December 12, 2013
Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infectionChing-I Huang, Chung-Feng Huang, Jee-Fu Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 6, 2022
Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular CarcinomaYu-Han Huang, Chi Chan, Hye-Won Lee, et al.
Pageof 46